Activation of Blood Coagulation Factor X by Arginine-specific Cysteine Proteinases (Gingipain-Rs) from Porphyromonas gingivalis*

(Received for publication, December 24, 1996, and in revised form, March 17, 1997)

Takahisa Imamura Dagger , Jan Potempa §, Sumio Tanase Dagger and James Travis

From the Department of Biochemistry, University of Georgia, Athens, Georgia 30602, the Dagger  Division of Molecular Pathology, Department of Neuroscience and Immunology, Kumamoto University Graduate School of Medical Sciences, Kumamoto 860, Japan, and the § Department of Microbiology and Immunology, Institute of Molecular Biology, Jagiellonian University, 31-120 Kraków, Poland

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The effect of two arginine-specific cysteine proteinases (gingipain Rs) from Porphyromonas gingivalis, a causative bacterium of adult periodontitis, on human blood coagulation was investigated. Activated partial thromboplastin time and prothrombin time were shortened by these proteinases, with a 95-kDa gingipain R containing adhesin domains being 5-fold more efficient in comparison to a 50-kDa gingipain R containing the catalytic domain alone. The 50-kDa enzyme reduced each coagulation time in several plasmas deficient in various coagulation factors, while it was ineffective in factor X-deficient plasma unless reconstituted with this protein. Each proteinase activated factor X in a dose- and time-dependent manner, with Michaelis constants (Km) being found to be lower than the normal plasma factor X concentration, strongly suggesting that factor X activation by gingipain Rs, especially the 95-kDa form which is strongly activated by phospholipids, could occur in plasma. This is the first report of factor X activation by bacterial proteinases and indicates that the gingipain Rs could be responsible for the production of thrombin and, indirectly, with the generation of prostaglandins, interleukin-1, etc., which have been found to be associated with the development of periodontitis induced by P. gingivalis infections. Furthermore, the data support the hypothesis that induction of blood coagulation by bacterial proteinases may be a causative agent in the pathogenesis of disseminated intravascular coagulation in sepsis.


INTRODUCTION

Periodontitis is an infectious disease associated with a loss of connective tissue, resorption of alveolar bone, and formation of periodontal pockets. It is the most common cause of tooth loss in adults, primarily because of the declining incidence of dental caries in the general population (1, 2). Although the pathogenesis of periodontitis is not completely understood, prostaglandins (3, 4) and interleukin-1 (5, 6), which increase in gingival crevicular fluid in periodontal pockets, are considered to be predominant factors in the tissue destruction process associated with this disease. However, the mechanism of the production of these inflammatory mediators is still unclear.

Thrombin, which is primarily associated with the cleavage of fibrinogen to generate fibrin clots (7-11), is a key proteinase in the blood coagulation system. However, besides its central role in hemostasis, this proteinase is also a potent stimulator of prostaglandin synthesis in osteoblasts (12), with in vitro bone resorption appearing to be dependent, at least in part, on thrombin-stimulated prostaglandin synthesis (13, 14). In addition, thrombin also potentiates lipopolysaccharide-stimulated interleukin-1 production by macrophages (15). These facts suggest that thrombin may play a major role in the development of periodontitis by indirectly causing tissue breakdown including alveolar bone resorption. However, whether thrombin is produced at periodontitis sites is still unknown.

A close relationship between Porphyromonas gingivalis (formally Bacteroides gingivalis) and adult periodontitis has been reported (16-18), with proteolytic enzymes which are produced in large quantity by this bacterium acting as important pathogenic agents (19-21). We have previously purified two arginine-specific cysteine proteinases, referred to as 50-kDa and 95-kDa gingipain1 Rs, from P. gingivalis (22, 23), and found each to be capable of generating bradykinin through prekallikrein activation (24) and degrading fibrinogen in human plasma (25). Both of these events may be potentially associated with crevicular fluid production and bleeding tendency, respectively, at periodontitis sites. The 95-kDa proteinase is composed of both a catalytic and an adhesin domain (26), the former being 81% identical in primary structure with that of the 50-kDa form.2 However, little is known with regard to any other specific functional differences between the two enzymes. Since coagulation factors are activated by cleavage of peptide bonds at the carboxyl-terminal side of specific arginine residues (27), it is possible that each of the gingipains Rs could activate the coagulation cascade system to produce thrombin, an enzyme known to have multiple functions. Therefore, to study other possible pathogenic roles for the two gingipain Rs, we investigated their effect on activating this system. It was found that each proteinase could induce blood coagulation through factor X activation. However, there were significant differences between 95-kDa gingipain R and the 50-kDa form in performing this function.


EXPERIMENTAL PROCEDURES

Materials

Human thrombin, benzoyl-L-arginine-p-nitroanilide (BA-pNA), tosyl-L-lysine chloromethylketone (TLCK), antipain, and plasmas deficient in factors VII, VIII, IX, X, XI, XII, or prekallikrein were purchased from Sigma. SIMPLASTIN®, AUTOMATED APTT, and Platelin® (rabbit brain phospholipids) were purchased from Organon Teknika, Corp. (Durham, NC) while D-Phe-L-Pro-L-Arg-chloromethylketone (FPR-ck) was obtained form Bachem Biosci. Inc. (King of Prussia, PA). Purified human factor X was purchased from Enzyme Research Laboratories, Inc. (South Bend, IN) and purified human factor Xa was acquired from Kaketsuken (Kumamoto, Japan). t-Butyloxycarbonyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-4-methyl-coumaryl-7-amide (Boc-Ile-Glu-Gly-Arg-MCA) was purchased from the Peptide Institute (Minoh, Japan). p-Nitrophenyl-p'-guanidinobenzoate was from Nacalai tesque (Kyoto, Japan). Normal human plasma was obtained by centrifugation of a mixture of 9 volumes of freshly drawn blood from healthy volunteers and 1 volume of 3.8% (w/v) sodium citrate.

Proteinase Purification

50-kDa gingipain R and 95-kDa gingipain R were isolated according to the method described by Pike et al. (23). The amount of active enzyme in each purified proteinase was determined by active site titration using FPR-ck.3 The concentration of active gingipain R was calculated from the amount of inhibitor needed for complete inactivation of the proteinase.

Activation of Proteinases

Each gingipain R form was activated with 10 mM cysteine in 0.2 M Hepes buffer, pH 8.0, containing 5 mM CaCl2 at 37 °C for 10 min. The activated proteinase (2 µM) was then diluted with 10 mM Tris-HCl, pH 7.3, containing 150 mM NaCl (TBS) and 5 mM CaCl2 prior to use.

Proteinase Activity Assay

The amidolytic activity of the gingipain Rs was determined using benzoyl-L-arginine-p-nitroaniline. Samples were preincubated at 37 °C for 5 min in 0.1 M Tris-HCl buffer, pH 7.6, containing 200 mM Gly-Gly, 5 mM CaCl2, and 10 mM cysteine, pH 7.6, and then assayed for amidolytic activity using 1 mM substrate. The formation of p-nitroaniline was monitored spectrophotometrically at 405 nm.

Clotting Assay

Clotting time was measured with COAG-A-MATE® XC (General Diagnostics, Morris Plains, NJ) following the manufacturer's instructions. For prothrombin time (PT) assay, 90 µl of plasma and 10 µl of a given proteinase were incubated in a plastic cell at 37 °C for 3 min, followed by addition 200 µl of SIMPLASTIN® to initiate coagulation. For activated partial thromboplastin time (APTT) assay, 90 µl of plasma and 10 µl of proteinase were incubated in a plastic cell at 37 °C for 1 min, followed by addition of 100 µl of AUTOMATED AAPTT®, incubation at 37 °C for 3 min, and addition of 100 µl of 25 mM CaCl2 to initiate coagulation.

Kinetic Analysis of Factor X Activation

Factor X, dissolved in 450 µl of 0.1 M Tris-HCl, pH 7.6, containing 0.15 M NaCl, 5 mM CaCl2, and 45 µg/ml phospholipids, was incubated with 50 µl of either of the gingipain Rs (0.5 nM) at 37 °C for 30, 60, 90, 120, or 150 s. One-hundred ml of the solution was then added to 500 µl of the same buffer supplemented with 1.5 µM antipain, to completely inhibit cysteine proteinase activity but not the amidolytic activity of factor Xa at the concentration used. This was followed by addition of 20 µl of a factor Xa-specific substrate, Boc-Ile-Glu-Gly-Arg-MCA (10 mM). The amount of 7-amino-4-methyl coumarin (AMC) released by factor Xa at 37 °C was measured fluorometrically with a fluorescence spectrophotometer (Model 650-40, Hitachi), the fluorescence at 440 nm with excitation at 380 nm being monitored with a recorder. The factor Xa concentration produced by either proteinase was calculated by using as a standard the amidolytic activity of purified factor Xa which had been active site-titrated with p-nitro-p'-guanidinobenzoate (28). The initial velocity of factor Xa production at various factor X concentrations was determined by the best fit line for each factor Xa concentration at the five incubation periods mentioned above. Several factor X concentrations in a range from 35 to 425 nM were used for the kinetic study.

The values of the Michaelis constant (Km) and the maximum velocity (Vmax) in the Michaelis-Menten equation were obtained using three different plots, [S]0/v versus [S]0, 1/v versus 1/[S]0 and v versus v/[S]0 (v and [S]0 denote the catalytic rate and the initial substrate concentration, respectively), where the best fit values were determined by the method of least squares with Taylor expansion, described by Sakoda and Hiromi (29).

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

Analysis by SDS-polyacrylamide gel electrophoresis was performed with 15% slab gels according to the method of Laemmli (30), with 0.8% Coomassie Brilliant Blue R-250 being used for protein staining.

Amino-terminal Sequence Analysis

Automatic sequence analysis was performed with a pulse-liquid phase sequencer (model 477A Protein Sequencer, Perkin-Elmer/Applied Biosystems Inc.). To determine the amino-terminal sequence of factor X-derived fragments, each protein fragment was separated by SDS-polyacrylamide gel electrophoresis and transferred to the ImmobilonTM polyvinylidene difluoride transfer membrane (Millipore Co., Ltd., Bedford, MA). The proteins transferred to the polyvinylidene difluoride membrane were visualized by staining with Coomassie Brilliant Blue R-250. The bands excised were placed on a Polybrene-treated glass filter and sequence analysis was performed.

Determination of Factor X Concentration

The molar concentrations of purified factor X were calculated using A280 nm1%[/stack = 13.3 and a molecular mass of 59 kDa (31).


RESULTS

Activation of Blood Coagulation by Gingipain Rs

To investigate the effect of gingipain Rs on blood coagulation, normal human plasma was incubated with either of the proteinases and examined for APTT. Both proteinases decreased APTT in a dose-dependent manner at concentrations as low as 0.1 nM, with the 95-kDa gingipain R being approximately 5-fold more effective than that of the 50-kDa gingipain R (Fig. 1). Since TLCK-treated proteinases did not shorten APTT (Fig. 1), the effect of gingipain Rs is dependent on their proteolytic activity. To investigate the mechanism for reducing APTT by gingipain Rs, the effect observed was further studied using plasmas deficient in a given factor found in the intrinsic coagulation pathway. The 50-kDa gingipain R shortened APTTs of plasmas deficient in factor XII, prekallikrein, XI, IX, or VIII in a dose-dependent manner (Table I). However, this enzyme did not affect the APTT of factor X-deficient plasma, unless it was reconstituted with the missing factor (Table I). It is suggested from these results that gingipain Rs shortened APTT through factor X activation. Normal human plasma incubated with either of the proteinases was also examined for PT to investigate the effect of gingipain Rs on the extrinsic pathway factors. It was again found that both proteinases reduced PT in a dose-dependent manner at concentrations above 1 nM, with the effect requiring active enzyme (Fig. 2). The 95-kDa gingipain R shortened the PT 5-fold more effectively than the 50-kDa form (Fig. 2), as previously observed in the case of APTT. The 50-kDa gingipain R also reduced PT of factor VII-deficient plasma, whereas there was little effect on the PT of factor X-deficient plasma, unless it was reconstituted with factor X (Table II). These data again suggest that gingipain R decreased PT through factor X activation and that accelerated blood coagulation induced by gingipain Rs is specifically due to activation of this factor.


Fig. 1. Activated partial thromboplastin time of normal human plasma incubated with the 50- or 95-kDa gingipain R. Ninety microliters of normal plasma was incubated with 10 µl of a proteinase for 1 min at 37 °C in a plastic cell, followed by addition of 100 µl of APTT reagent (AUTOMATED APTT). After incubation at 37 °C for 5 min, 100 µl of 25 mM CaCl2 was added to the mixture and measured the clotting time with COAG-A-MATE® XC. The value is expressed the average ± S.D. in triplicate assay. The proteinase concentrations in plasma are shown. open circle , 50-kDa gingipain R; triangle , 95-kDa gingipain R; bullet  TLCK-inactivated 50 kDa-gingipain R; black-triangle, TLCK-inactivated 95-kDa gingipain R. Dashed lines are borders of controls which were assayed using 10 mM Tris-HCl, pH 7.3, containing 150 mM NaCl (TBS) instead of the 50-kDa gingipain R. In the case of clotting within 20 s, this assay is not available.
[View Larger Version of this Image (14K GIF file)]

Table I. Effect of 50-kDa gingipain R on activated partial thromboplastin time of plasmas deficient in a factor in the intrinsic coagulation pathway

The effect of 50-kDa gingipain R on activated partial thromboplastin time was examined in plasmas deficient in a factor utilized in the intrinsic pathway, according to the method shown in Fig. 1. The value was expressed as the average ± S.D. in triplicate assay.

Plasmaa Clotting time (s) 50-kDa gingipain R concentrationb
(-) 10 nM 30 nM

Normal 34.5  ± 0.5 23.1  ± 0.5 <20c
Factor XII-deficient 219.6  ± 1.7 37.4  ± 1.9 22.7  ± 0.2
Prekallikrein-deficient 92.2  ± 2.7 42.6  ± 1.6 <20c
Factor XI-deficient 92.4  ± 2.5 29.3  ± 0.7 22.3  ± 0.1
Factor IX-deficient 101.5  ± 1.7 51.1  ± 2.9 31.4  ± 0.2
Factor VIII-deficient 96.7  ± 3.5 26.1  ± 0.5 <20c
Factor X-deficient 189.1  ± 9.8 204.6  ± 5.2 201.5  ± 9.6
Factor X-deficient-reconstitutedd 32.9  ± 0.4 22.9  ± 0.3 <20c

a Diluted 2-fold with Tris-buffered saline.
b The concentration in the plasma.
c Clotted within 20 s, the detection limit.
d Factor X-deficient plasma reconstituted with 9 µg/ml factor X.


Fig. 2. Prothrombin time of normal human plasma incubated with the 50- or 95-kDa gingipain R. Ten microliters of a proteinase was added to 90 µl of normal plasma and incubated at 37 °C for 3 min in a plastic cell. Then, 200 µl of prothrombin time reagent (SIMPLASTIN®) was added to the mixture and the clotting time was measured with COAG-A-MATE® XC. The value is expressed the average ± S.D. in triplicate assay. The proteinase concentration in plasma is shown. open circle , 50-kDa gingipain R; triangle , 95-kDa gingipain R; bullet , TLCK-inactivated 50-kDa gingipain R; black-triangle, TLCK-inactivated 95-kDa gingipain R. Dashed lines are borders of controls which were assayed using TBS instead of a proteinase.
[View Larger Version of this Image (15K GIF file)]

Table II. Effect of 50-kDa gingipain R on prothrombin time of plasmas deficient in a factor in the extrinsic pathway

The effect of 50-kDa gingipain R on prothrombin time was examined in plasmas deficient in a factor in the extrinsic pathway, according to the method shown in Fig. 2. The value was expressed as the average ± S.D. in triplicate assay.

Plasma 50-kDa gingipain R (100 nM) Clotting time

(s)
Normal  - 11.6  ± 0.2
Normal + 10.0  ± 0.1
Factor VII-deficient  - 41.9  ± 1.2
Factor VII-deficient + 25.2  ± 3.7
Factor X-deficienta  - 99.3  ± 1.5
Factor X-deficient + 90.7  ± 2.2
Factor X-deficient-reconstituted  - 12.1  ± 0.3
Factor X-deficient-reconstituted + 10.5  ± 0.3

a Factor X-deficient plasma reconstituted with 9 µg/ml purified factor X.

Activation of Factor X by Gingipains Rs

To investigate factor X activation by gingipain Rs, we incubated these cysteine proteinases with purified factor X and measured the factor Xa activity produced. Both proteinases generated factor Xa linearly in a dose- and time-dependent manner (Fig. 3, A and B). Consistent with the data shown in Figs. 1 and 2, the 95-kDa gingipain R produced more factor Xa than the 50-kDa gingipain R (Fig. 3, A and B). TLCK-treated gingipain Rs did not induce factor X activation (Fig. 3A).


Fig. 3. Activation of factor X by the 50- or 95-kDa gingipain R. Ten microliters of a proteinase was added to 90 µl of factor X (1 µM dissolved in 0.1 M Tris-HCl, pH 7.6, 150 mM NaCl, and 5 mM CaCl2) and incubated at 37 °C. Then, 500 µl of the above buffer supplemented with 1.5 µM antipain was added to stop the activation. Twenty microliters of Boc-Ile-Glu-Gly-Arg-MCA (10 mM) was added to the solution and the velocity of AMC release was measured at 37 °C. A, proteinases of various concentrations were incubated with factor X for 5 min. The final concentrations of each proteinase are shown. open circle , 50-kDa gingipain R; triangle , 95-kDa gingipain R; bullet , TLCK-inactivated 50-kDa gingipain R; black-triangle, TLCK-inactivated 95-kDa gingipain R. B, a proteinase (0.05 nM, the final concentration) was incubated with factor X at 37 °C for various periods. µ, 50-kDa gingipain R; q, 95-kDa gingipain R; open circle , TBS instead of a proteinase solution.
[View Larger Version of this Image (16K GIF file)]

Cleavage of Factor X by the 50-kDa Gingipain R

To investigate the mechanism of factor X activation by gingipain R in more detail, we examined the pattern of cleavage during this process on an SDS-polyacrylamide gel, followed by amino-terminal sequence analysis of the fragments generated. Treatment with proteinase did not shift the 21-kDa molecule, which had an amino-terminal sequence ANSFLXXMKK (X is presumed to be delta -carboxyglutamic acid) identical to that of the factor X light chain (Fig. 4). This indicates that cleavage had only occurred within the heavy chain which contains the catalytic domain blocked by the activation peptide. Our data also suggests that the first cleavage by gingipain R resulted in a shift in molecular mass from 47 to 45 kDa (lane b) without affecting the amino-terminal sequence (SVAQATSSSG-), presumably because of hydrolysis between Arg278-Gly288 and release of a 19-amino acid peptide. This is consistent with the fact that the molecular mass of the final form of the heavy chain is slightly smaller than that of the factor Xa heavy chain (lanes d and e). The amino-terminal sequences of the 35- and 32-kDa molecules were GDNNLTRIVG- and IVGGQECKDG-, respectively. From the amino acid sequence of human factor Xa (32), the generation of the 35-kDa fragment must have occurred through cleavage between Arg45 and Gly46 within the modified heavy chain to release a 45-amino acid activation glycopeptide. Finally, cleavage must occur between Arg52 and Ile53 to release the remainder of the activation peptide, also glycosylated. All of these proteolysis sites are in agreement with the fact that gingipain Rs only cleave polypeptide chains after arginine residues (22, 23) and at positions which are consistent with the activation of Factor X to Factor Xa.


Fig. 4. Cleavage of factor X by the 50-kDa gingipain R. Forty microliters of factor X (10 µM), dissolved in 0.1 M Tris-HCl, pH 7.6, 150 mM NaCl, and 5 mM CaCl2, was incubated with 10 µl of a proteinase (0.02 µM) at 37 °C for 5, 15, or 60 min. Ten microliters of the solution was applied for SDS-polyacrylamide gel electrophoresis in the presence of 2 mM beta -mercaptoethanol. a, factor X only; b, c, and d, factor X incubated with 50-kDa gingipain R for 5, 15, or 60 min, respectively; e, factor Xa (0.8 µM); f, molecular mass markers (phosphorylase b, 94 kDa; bovine serum albumin, 67 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa; alpha -lactalbumin, 13 kDa).
[View Larger Version of this Image (101K GIF file)]

Effect of Phospholipids on Gingipain R Factor X Activation

Phospholipids are important cofactors in blood coagulation and accelerate the cascade reaction of coagulation factors. We, therefore, studied the effect of phospholipids on factor X activation by gingipain Rs. 95-kDa gingipain R factor Xa production increased in a phospholipid concentration-dependent manner with the effect reaching a plateau at concentrations above 40 µg/ml, and yielding a 7-8-fold increase in factor X activation at enzyme concentrations of both 0.02 and 0.05 nM (Fig. 5). Interestingly, phospholipids did not stimulate the activation of factor X by the 50-kDa gingipain R (Fig. 5). Phospholipids did not augment 95-kDa gingipain R factor X activation in the absence of calcium, while factor X activation by the two proteinases was not affected by calcium in the absence of phospholipids (Fig. 5). It is likely that the calcium ion-mediated binding of the adhesin domains to phospholipids, in addition to factor X binding, is involved in augmentation of the factor X activation.


Fig. 5. Effect of phospholipids on factor X activation by the 50- or 95-kDa gingipain R. Ten microliters of a proteinase was added to a mixture of 80 µl of factor X (1.25 µM dissolved in 0.1 M Tris-HCl, pH 7.6, 150 mM NaCl supplemented with (open symbols) or without (solid symbols) 5 mM CaCl2) and 10 µl of phospholipids. After a 5-min incubation at 37 °C, 500 µl of the above buffer supplemented with 1.5 µM antipain was added to the mixture to stop the activation. Twenty microliters of Boc-Ile-Glu-Gly-Arg-MCA (10 mM) was added to the solution and the velocity of AMC release was measured at 37 °C. open circle , bullet , 50-kDa gingipain R (50 pM); triangle  and black-triangle, 95-kDa gingipain R (50 pM); down-triangle, 95 kDa-gingipain R (20 pM).
[View Larger Version of this Image (20K GIF file)]

Kinetics of Factor X Activation by Gingipain Rs

To investigate the kinetics of factor X activation by gingipain Rs, the values of Km and kcat were determined for the interaction of purified factor X with either enzyme at a phospholipid concentration of 40 µg/ml. The values of Km and kcat were 98 nM and 0.4/s for 95-kDa gingipain R and 136 nM and 0.012/s for 50-kDa gingipain R (Figs. 6, A and B), the catalytic efficiency (kcat/Km) of the former enzyme being 46-fold higher than that of the 50-kDa gingipain R. This result does not appear to be consistent with the fact that the 95-kDa gingipain R activated blood coagulation 5~6-fold more efficiently than the 50-kDa gingipain R (Figs. 1 and 2). This is probably because Ca2+ are absent during the incubation of plasma with each proteinase and added just before coagulation initiation, resulting in a lessened effect of phospholipids on 95-kDa gingipain R-stimulated factor X activation. The kinetic constants of gingipain Rs for factor X conversion were compared with those of activated factor VII (VIIa) complexed with tissue factor (factor VIIa-TF) (33), factor IX complexed with activated factor VIII (VIIIa) (34), or Russell's viper venom factor X coagulant protein (RVV-XCP), a factor X-specific activator (34). The Km values of the cysteine proteinases were higher than those of physiological factor X activators but lower than the Km value of RVV-XCP (Table III). The kcat values of gingipain Rs were lower than any of other factor X activators, but the kcat value of 95-kDa gingipain R was close to the values of factor VIIa-TF and RVV-XCP (Table III). The kcat/Km value was much lower than the values of physiological factor X activators but was about half of the value of RVV-XCP. These data suggest that 95-kDa gingipain R is a more potent factor X activator than the 50-kDa form and is comparable to RVV-XCP in factor X activation.


Fig. 6. Kinetic study of factor X activation by gingipain Rs. The initial velocities of factor X activation by 50-kDa gingipain R (A) or 95-kDa gingipain R (B) were determined under the conditions described under "Experimental Procedures." The concentrations of a proteinase and phospholipids were 50 pM and 40 µg/ml, respectively. [S]0/v versus [S]0 plots of the data were shown in each inset.
[View Larger Version of this Image (23K GIF file)]

Table III. Kinetic constants for the activation of Factor X


Enzymes Km kcat kcar/Km

M s-1 M-1 S-1
50-kDa gingipain R 1.4  × 10-7 1.2 × 10-2 8.9  × 104
95-kDa gingipain R 9.8  × 10-8 0.4 4.1  × 106
Factor VIIa-TFa 5.5  × 10-8 1.3 2.4  × 107
Factor IXa-VIIIab 6.0  × 10-8 17 2.8  × 108
RVV-XCPc 2.4  × 10-7 2.3 9.6  × 106

a Data obtained from Ref. 32.
b Data obtained from Ref. 34. Factor VIIa-TF was activated factor VII complexed with tissue-factor apoprotein; factor IXa-VIIa, activated factor IX complexed with activated factor VIII.
c RVV-XCP, Russell's viper venom factor X coagulant protein.


DISCUSSION

In this study we have provided experimental evidence to support the hypothesis that gingipain Rs can induce blood coagulation through activation of factor X. Although snake venom enzymes are known to activate factor X (35, 36), no bacterial proteinase has been reported so far to perform this same function. Indeed, staphylocoagulase is the only bacterial coagulase which can induce human plasma coagulation, apparently through formation of an active molecular complex with prothrombin (37). The present work, therefore, demonstrates the existence of factor X activators of bacterial origin for the first time. Previously, it has been shown that gingipain Rs can activate prekallikrein and convert it to kallikrein (24), an activator of Hageman factor (38) which initiates the intrinsic coagulation pathway (39). Accordingly, it is possible that gingipain Rs trigger blood coagulation through this mechanism. However, this pathway is unlikely to be involved in gingipain R-induced blood coagulation, since the APTT of prekallikrein-deficient plasma, like other deficient plasmas (except factor X-deficient plasma), is also shortened by 50-kDa gingipain R (Table I). Furthermore, this bacterial proteinase also shortened PT of factor VII-deficient plasma but not of factor X-deficient plasma (Table II). Thus, it seems likely that the factor X activation by gingipain Rs is the primary site through which blood coagulation is induced by these proteinases.

The Km values of gingipain Rs (Table III) are lower than the factor X concentration in normal plasma (around 10 µg/ml, 170 nM) (27), which, together with their effects on APTT and PT (Figs. 1 and 2), supports the hypothesis that factor X activation by gingipain Rs can occur in plasma. Since phospholipids and calcium ions are ubiquitous cell membrane components and ions, respectively, their stimulatory effect on 95-kDa gingipain R-induced factor X activation (Fig. 5) can occur in vivo. Together with the fact that the kcat/Km value is close to the value of RVV-XCP (Table III), a strong factor X activator, it is likely that the high molecular weight gingipain R is physiologically a more important factor X activator than the smaller form.

We previously reported the binding activity of the adhesin domains in high molecular mass forms of gingipains to various proteins (40). The fact that the phopholipids augment factor X activation only by 95-kDa gingipain R (Fig. 5), complexed with adhesin domains, suggest the binding of the adhesin domains to phospholipids. Exoenzyme S, recently confirmed as an adhesin for Pseudomonas aeruginosa (41), binds to phosphatidylethanolamine specifically in the presence of 5 mM CaCl2 (42) and lipid receptors have been shown to be involved in the binding of Helicobacter pylori and Burkholderia (Basonym Pseudomonas) cepacis to epithelial cells (42, 43). Thus, it may be natural for 95-kDa gingipain R adhesin domains to bind to phospholipids. However, phospholipids augmented neither Boc-Ile-Glu-Gly-Arg-MCA hydrolysis, prekallikrein activation, nor fibrinogen degradation by the complexed form,4 hence the phospholipids effect appears to be specific for factor X activation. The augmentation of 95-kDa gingipain R factor X activation by phospholipids, together with the lower Km and much higher kcat values of 95-kDa gingipain R than those of the 50-kDa form (Table III), indicates a further function for the adhesin domains in increasing the affinity to factor X as well as facilitating substrate cleavage.

In human plasma, gingipain Rs generate bradykinin (24), a potent vascular permeability enhancing peptide. In parallel, and through factor X activation thrombin is also generated (Fig. 1 and 2). Thus, in blood there is likely to be the simultaneous production of each by gingipain Rs, and for this reason it is believed that both may also be involved in the production of gingival crevicular fluid (24) and of prostaglandins and interleukin-1 (13-15), respectively, during infectious episodes. Hence, the elevated levels of prostaglandins and interleukin-1 in gingival crevicular fluid of adult periodontitis patients (3, 4, 6) may be connected to the thrombin produced by P. gingivalis proteinases. In addition, thrombin and fibrinopeptide B, released from fibrinogen by thrombin are each neutrophil chemotactic factors (44, 45) and may contribute to infiltration of these phagocytic cells at periodontitis sites (46). Finally, factor Xa also enhances macrophage interleukin-1 production (15) and is mitogenic for endothelial cells (47), smooth muscle cells (48), and lymphocytes (49). Therefore, the data described here would imply that gingipain R-induced activation of blood coagulation through conversion of factor X to Xa can easily be involved in the development of periodontitis.

In septic patients, disseminated intravascular coagulation (DIC) occurs frequently. Recent studies indicate that the initial activation of coagulation in sepsis is primarily dependent on activation of the extrinsic pathway, initiated by tissue factor expressed on monocytes (50). Since endotoxin, itself, or endotoxin-induced tumor necrosis factor-alpha can stimulate monocytes to express tissue factor (51, 52), the tendency has been to recognize such factors as the primary bacterial agents involved in the induction of DIC coagulation in sepsis. However, our finding that gingipain Rs can also readily induce blood coagulation suggest the possibility of bacterial proteinase-induced DIC coagulation in sepsis. It has been reported that a patient with an acute dentoalveolar abscess developed septicemia of Bacteroides melaninogenicus, a bacterium similar to P. gingivalis, and died with DIC (53). The fact that no plasma proteinase inhibitor effectively inactivates gingipain Rs (data not shown) supports this possibility. If so, inhibitors of such enzymes could be a therapy for DIC.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant DE 09761 (to J. T.) and Grant 6 P204A 019 11 from Committee of Scientific Research (KBN, Poland) (to J. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Dept. of Biochemistry, University of Georgia, Athens, GA 30602. Tel.: 706542-1711; Fax: 706-542-3719; E-mail: jtravis{at}uga.cc.uga.edu.
1   The abbreviations used are: gingipain R, arginine-specific gingipain; PT, prothrombin time; APTT, activated partial thromboplastin time; TLCK, tosyl-L-lysine chloromethyl ketone; factor Xa, activated coagulation factor X; DIC, disseminated intravascular coagulation.
2   J. Potempa, unpublished data.
3   J. Potempa, R. Pike, and J. Travis, manuscript in preparation.
4   T. Imamura, unpublished data.

REFERENCES

  1. Shaw, J. H. (1987) N. Eng. J. Med. 317, 996-1004 [Medline] [Order article via Infotrieve]
  2. Williams, R. C. (1990) N. Eng. J. Med. 322, 373-382 [Medline] [Order article via Infotrieve]
  3. Offenbacher, S., Odle, B. M., and Van Dyke, T. E. (1986) J. Periodont. Res. 21, 101-112 [Medline] [Order article via Infotrieve]
  4. Tubb, M., Williams, F. E., and Fraizier, L. W. (1990) Arch. Oral. Biol. 35, 529-533 [Medline] [Order article via Infotrieve]
  5. Hönig, J., Rordorf-Adam, C., Siegmund, C. W., Wiedemann, W., and Erard, F. (1989) J. Periodont. Res. 24, 362-367 [Medline] [Order article via Infotrieve]
  6. Masada, M. P., Persson, R., Kenney, J. S., Lee, S. W., Page, R. C., and Allison, A. C. (1990) J. Periodont. Res. 25, 156-163 [Medline] [Order article via Infotrieve]
  7. Fenton, J. W., II (1986) Ann. N. Y. Acad. Sci. 485, 5-15 [Medline] [Order article via Infotrieve]
  8. Colman, R. W., Marder, V. J., Salzman, E. W., and Hirsh, J. (1987) in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W., Hirsh, J., Marder, V. J., and Salzman, E. W., eds), 2nd Ed., pp. 3-17, J. B. Lippincott, Philadelphia, PA
  9. Mann, K. G., R., and Lundblad, L. (1987) in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W., Hirsh, J., Marder, V. J., and Salzman, E. W., eds), 2nd Ed., pp. 148-161, J. B. Lippincott, Philadelphia, PA
  10. Furie, B., and Furie, B. C. (1988) Cell 53, 505-518 [Medline] [Order article via Infotrieve]
  11. Nemerson, Y. (1988) Blood 71, 1-8 [Medline] [Order article via Infotrieve]
  12. Partridge, N. C., Hillyard, C. J., Nolan, R. D., and Martin, T. J. (1985) Prostaglandins 30, 527-539 [Medline] [Order article via Infotrieve]
  13. Hoffmann, O., Klaushofer, K., Koller, K., Peterlik, M., Mavreas, T., and Stern, P. (1986) Prostaglandins 31, 601-608 [Medline] [Order article via Infotrieve]
  14. Lerner, U. H., and Gustafson, G. T. (1988) Biochim. Biophys. Acta 964, 309-318 [Medline] [Order article via Infotrieve]
  15. Jones, A., and Geczy, C. L. (1990) Immunology 71, 236-241 [Medline] [Order article via Infotrieve]
  16. Slots, J. (1982) in Host-Parasite Interactions in Periodontal Diseases (Genco, R. J., and Mergenhagen, S. E., eds), pp. 27-45, American Society of Microbiology, Washington, D. C.
  17. Holt, S. C., Ebersole, J., Fenton, J., Brunsvold, M., and Kornman, K. S. (1987) Science 239, 55-57
  18. Zambon, J. J. (1990) in Contemporary Periodontics (Genco, R. J., Goldman, H. M., and Cohen, D. W., eds), pp. 147-160, CV Mosby, St. Louis, MO
  19. Grenier, D., and Mayrand, D. (1987) J. Clin. Microbiol. 25, 738-740 [Medline] [Order article via Infotrieve]
  20. Smalley, J. W., Birss, A. J., Kay, H. M., McKee, A. S., and Marsh, P. D. (1989) Oral Microbiol. Immunol. 4, 178-181 [Medline] [Order article via Infotrieve]
  21. Marsh, P. D., McKee, A. S., McDermid, A. S., and Dowsett, A. B. (1989) FEMS Microbiol. Lett. 59, 181-185
  22. Chen, Z., Potempa, J., Polanowski, A., Wikstrom, M., and Travis, J. (1992) J. Biol. Chem. 267, 18896-18901 [Abstract/Free Full Text]
  23. Pike, R, McGraw, W., Potempa, J., and Travis, J. (1994) J. Biol. Chem. 269, 406-411 [Abstract/Free Full Text]
  24. Imamura, T., Pike, R. N., Potempa, J., and Travis, J. (1994) J. Clin. Invest. 94, 361-367 [Medline] [Order article via Infotrieve]
  25. Imamura, T., Potempa, J., Pike, R. N., Moore, J. N., Barton, M. H., and Travis, J. (1995) Infect. Immun. 63, 4877-4882 [Abstract]
  26. Pavloff, N., Potempa, J., Pike, R. N., Prochazka, V., Kiefer, M. C., Travis, J., and Barr, P. J. (1995) J. Biol. Chem. 270, 1007-1010 [Abstract/Free Full Text]
  27. Halkier, T. (1991) Mechanisms in Blood Coagulation, Fibrinolysis, and the Complement System, Cambridge University Press, Cambridge, United Kingdom
  28. Chase, T., Jr., and Shaw, E. (1967) Biochem. Biophys. Res. Commun. 29, 508-514
  29. Sakoda, M., and Hiromi, K. (1976) J. Biochem. 80, 547-555 [Abstract]
  30. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  31. DiScipio, R. G., Hermodson, M. A., Yates, S. G., and Davie, E. W. (1977) Biochemistry 16, 698-706 [Medline] [Order article via Infotrieve]
  32. Leytus, S. P., Chung, D. W., Kisiel, W., Kurachi, K., and Davie, E. W. (1984) Proc. Natl. Acad. Sci U. S. A. 81, 3699-3702 [Abstract]
  33. Bom, V. J. J., and Bertina, R. M. (1990) Biochem. J. 265, 327-336 [Medline] [Order article via Infotrieve]
  34. Duffy, E. J., and Lollar, P. (1992) J. Biol. Chem. 267, 7821-7827 [Abstract/Free Full Text]
  35. Kisiel, W., Hermodson, M. A., and Davie, E. W. (1976) Biochemistry 15, 4901-4906 [Medline] [Order article via Infotrieve]
  36. Farid, T., Nasser, H., Zaki, K., and el-Asmar, M. F. (1993) Toxicon 31, 1007-1017 [Medline] [Order article via Infotrieve]
  37. Hemker, H. C., Bass, B. M., and Muller, A. D. (1975) Biochim. Biophys. Acta 379, 180-188 [Medline] [Order article via Infotrieve]
  38. Cochrane, C. G., Revak, S. D., and Wuepper, K. D. (1973) J. Exp. Med. 138, 1564-1583 [Medline] [Order article via Infotrieve]
  39. Cochrane, C. G., and Griffin, J. H. (1982) Adv. Immunol. 33, 241-306 [Medline] [Order article via Infotrieve]
  40. Pike, R. N., Potempa, J., McGraw, W., Coetzer, T. H. T., and Travis, J. (1996) J. Bacteriol. 178, 2876-2882 [Abstract]
  41. Baker, N. R., Minor, V., Deal, C., Sahrabadi, M. S., Simpson, D. A., and Wooda, D. E. (1991) Infect. Immun. 59, 2859-2863 [Medline] [Order article via Infotrieve]
  42. Lingwood, C. A., Huesca, M., and Kuksis, A. (1992) Infect. Immun. 60, 2470-2474 [Abstract]
  43. Sylvester, F. A., Sajjan, U. S., and Forstner, J. F. (1996) Infect. Immun. 64, 1420-1425 [Abstract]
  44. Bizios, R., Lai, L., Fenton, J. W., II, and Malik, J. B. (1986) J. Cell. Physiol. 128, 485-490 [Medline] [Order article via Infotrieve]
  45. Senior, R. M., Skogen, W. F., Griffin, G. L., and Wilner, G. D. (1986) J. Clin. Invest. 77, 1014-1019 [Medline] [Order article via Infotrieve]
  46. Williams, D. M., Hughes, F. J., Odell, E. W., and Farthing, P. M. (1992) Pathology of Periodontal Disease, p. 90, Oxford University Press, Oxford, United Kindgom
  47. Gajdusek, C., Carbon, S., Ross, R., Nawroth, P., and Stern, D. (1986) J. Cell Biol. 103, 419-428 [Abstract]
  48. Gasic, G. P., Arenas, C. P., Gasic, T. B., and Gasic, G. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2317-2320 [Abstract]
  49. Altieri, D. C. (1994) Cell. Immunol. 155, 372-383 [CrossRef][Medline] [Order article via Infotrieve]
  50. Levi, M., ten Cate, H., van der Poll, T., and van Deventer, S. J. H. (1993) J. Am. Med. Assoc. 270, 975-979 [Abstract]
  51. Rivers, R. P., Hathaway, W. E., and Weston, W. L. (1975) Br. J. Haematol. 30, 311-316 [Medline] [Order article via Infotrieve]
  52. Conkling, P. R., Greenberg, C. S., and Weinberg, J. B. (1988) Blood 72, 128-133 [Abstract]
  53. Currie, W. J. R., and Ho, V. (1993) Br. J. Oral Maxillofac. Surg. 31, 296-298 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.